Stereotactic Ablative Body Radiosurgery (SABR)

RADIATION2 trials

Sponsors

Peter MacCallum Cancer Centre, Australia

Conditions

Bone NeoplasmsBreast NeoplasmsRenal Cell Carcinoma

Phase 1

Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475

CompletedNCT02303366

Peter MacCallum Cancer Centre, AustraliaBone Neoplasms, Breast Neoplasms

Start: 2015-09-30End: 2017-04-30Updated: 2017-10-18

Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours

CompletedNCT02855203

Peter MacCallum Cancer Centre, AustraliaRenal Cell Carcinoma

Start: 2016-10-20End: 2020-05-22Updated: 2023-08-03

Related Papers

Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.

2026-07-08

Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial.

2021-12-23103 citations

Stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumors: The RAPPORT trial.

Journal of Clinical Oncology2021-02-2016 citations

A phase I/II study of stereotactic radiotherapy and pembrolizumab for oligometastatic renal tumours (RAPPORT): Clinical trial protocol

Contemporary Clinical Trials Communications2021-01-107 citations